Ixekizumab (Taltz®) is indicated for the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||16/10/2018|
|Rapid review completed||19/11/2018|
|Rapid Review outcome||A Full pharmacoeconomic assessment is not recommended. The NCPE recommends that ixekizumab not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013|